Cargando…

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series

Detalles Bibliográficos
Autores principales:	Yang, Stephen Su, Boudjemai, Rosa, Lipes, Jed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584922/ https://www.ncbi.nlm.nih.gov/pubmed/33189533 http://dx.doi.org/10.1053/j.jvca.2020.10.040

Ejemplares similares

Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series
por: Yang, Stephen Su, et al.
Publicado: (2020)

Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients
por: Xu, Lengnan, et al.
Publicado: (2022)

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
por: Zhang, Chi, et al.
Publicado: (2020)

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
por: Rajendram, Prabalini, et al.
Publicado: (2021)

Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
por: Woxholt, Sindre, et al.
Publicado: (2023)

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
por: Liu, Danfei, et al.
Publicado: (2020)

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
por: Price, Christina C., et al.
Publicado: (2020)

Re: ‘Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review’ by Serafim et al.
por: Lipes, Jed, et al.
Publicado: (2021)

Severe and critical COVID-19 in pregnancy: A case series from Montreal
por: Trahan, Marie-Julie, et al.
Publicado: (2021)

Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2
por: Corominas, Hèctor, et al.
Publicado: (2021)

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Publicado: (2021)

Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019
por: Betts, Brian C., et al.
Publicado: (2020)

Care of critically ill pregnant patients with coronavirus disease 2019: a case series
por: Hirshberg, Adi, et al.
Publicado: (2020)

Effect of tocilizumab treatment in mildly-obese patients with coronavirus disease 2019: a case series
por: Abe, Takashi, et al.
Publicado: (2022)

Use of CytoSorb therapy to treat critically ill coronavirus disease 2019 patients: a case series
por: Mehta, Yatin, et al.
Publicado: (2021)

Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

The effect of tocilizumab on cytokine release syndrome in COVID-19 patients
por: de Cáceres, Carmen, et al.
Publicado: (2020)

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
por: Hassoun, Ali, et al.
Publicado: (2020)

Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series
por: Nakamura, Hideta, et al.
Publicado: (2020)

Tocilizumab in the treatment of coronavirus disease 2019 pneumonia: real-world data from a case series
por: Cui, Ran, et al.
Publicado: (2021)

The Association of Inflammatory Cytokines in the Pulmonary Pathophysiology of Respiratory Failure in Critically Ill Patients With Coronavirus Disease 2019
por: Stukas, Sophie, et al.
Publicado: (2020)

Interleukin-6: obstacles to targeting a complex cytokine in critical illness
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study
por: Al Sulaiman, Khalid, et al.
Publicado: (2021)

Thrombotic Complications in a Canadian Population of Critically Ill Patients with COVID-19
por: Camille, Simard, et al.
Publicado: (2020)

Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019
por: Mombrun, Martin, et al.
Publicado: (2021)

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
por: Uslu, Sadettin
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients
por: Piagnerelli, Michaël, et al.
Publicado: (2020)

Carboxyhemoglobinemia in Critically Ill Coronavirus Disease 2019 Patients
por: Faisal, Hina, et al.
Publicado: (2021)

Volatile Isoflurane in Critically Ill Coronavirus Disease 2019 Patients—A Case Series and Systematic Review
por: Flinspach, Armin Niklas, et al.
Publicado: (2020)

Cytomegalovirus reactivation in critically-ill Coronavirus Disease 2019 patients: A case series of 11 patients
por: Kim, Myeongji, et al.
Publicado: (2022)

The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill
por: Knight, Jennifer M., et al.
Publicado: (2021)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

Tocilizumab in critically ill COVID-19 patients: An observational study
por: Mushtaq, Muhammad Z., et al.
Publicado: (2022)

Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series
por: Mady, Ahmed, et al.
Publicado: (2020)

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
por: Veiga, Viviane C, et al.
Publicado: (2021)

Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
por: Melody, Megan, et al.
Publicado: (2020)

Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review
por: Jorgensen, Sarah C.J., et al.
Publicado: (2022)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

Convalescent Plasma Therapy in Four Critically Ill Pediatric Patients With Coronavirus Disease 2019: A Case Series
por: Schwartz, Stephanie P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3m0jn8f9g64e5u7i43cpv38pu4